Aminocaproic acid
Back to search| Scientific Name: | Aminocaproic acid |
| Brand Name: | Amicar |
| Company Owner: | Xanodyne pharmaceutics inc, Abraxis pharmaceutical products, Baxter healthcare corp anesthesia and critical care, Hospira inc, Luitpold pharmaceuticals inc, Mikart inc |
| Mechanism Of Action | Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a) a has two components, apolipoprotein B-100, linked to apolipoprotein (a) . Aminocaproic acid may change the conformation of apoliprotein (a) , changing its binding properties and potentially preventing the formation of lipoprotein (a) . |
| Description of the Drug: | Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. |
| Protein Data Bank: |
|
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00513
